Want to see IN:VIYASH full AI Analyst Report?
VIYASH Stock Chart & Stats
₹210.65
-₹3.94(-2.00%)
At close: 4:00 PM EST
₹210.65
-₹3.94(-2.00%)
Day’s Range― - ―
52-Week Range₹166.20 - ₹297.90
Previous CloseN/A
VolumeN/A
Average Volume (3M)119.95K
Market Cap
₹121.84B
Enterprise Value₹52.38K
Total Cash (Recent Filing)₹2.70B
Total Debt (Recent Filing)₹4.90B
Price to Earnings (P/E)86.3
Beta1.25
Next Earnings
Aug 12, 2026Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.25
Shares Outstanding436,875,500
10 Day Avg. Volume209,903
30 Day Avg. Volume119,946
Financial Highlights & Ratios
PEG Ratio0.12
Price to Book (P/B)2.72
Price to Sales (P/S)2.32
P/FCF Ratio61.41
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)9.45
Revenue Forecast (FY)₹39.17B
Bulls Say, Bears Say
Bulls Say
Revenue GrowthA >100% revenue jump in 2026 reflects meaningful demand recovery or successful commercialization of products. Sustained top-line momentum improves scale economics, funds reinvestment and reduces per-unit costs, supporting durable profitability if management preserves growth execution.
Margin ImprovementMaterial margin expansion to mid-teens operating margins and high-teens EBITDA signals better cost control and operating leverage. If sustained, this enhances cash generation capacity, underwrites reinvestment or deleveraging, and makes the business structurally more profitable.
Stronger Balance SheetMarked leverage reduction and equity expansion materially lower financial risk and interest burden. A healthier capital structure increases strategic flexibility for capex, R&D or M&A and improves resilience to industry cycles over the medium term.
Bears Say
Earnings VolatilityRecent history of losses highlights uneven demand, execution risks or product-cycle exposure. Such volatility undermines confidence that the 2026 rebound is sustainable and raises the probability of future profit deterioration absent structural fixes.
Weak Cash ConversionFCF materially trailing accounting earnings and low operating cash as a share of revenue indicate sensitivity to working capital and capex. Limited cash conversion constrains ability to repay debt, invest, or return capital despite reported profits.
Margin Stability RiskWide margin swings suggest earnings are influenced by one-offs, pricing pressure or cost variability. Persistent margin instability complicates long-term planning, makes cash flows less predictable, and increases execution risk for sustaining recent profitability.
Viyash Scientific News
VIYASH FAQ
What was Viyash Scientific Limited’s price range in the past 12 months?
Viyash Scientific Limited lowest stock price was ₹166.20 and its highest was ₹297.90 in the past 12 months.
What is Viyash Scientific Limited’s market cap?
Viyash Scientific Limited’s market cap is ₹121.84B.
When is Viyash Scientific Limited’s upcoming earnings report date?
Viyash Scientific Limited’s upcoming earnings report date is Aug 12, 2026 which is in 26 days.
How were Viyash Scientific Limited’s earnings last quarter?
Viyash Scientific Limited released its earnings results on May 19, 2026. The company reported ₹1.17 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.
Is Viyash Scientific Limited overvalued?
According to Wall Street analysts Viyash Scientific Limited’s price is currently Overvalued.
Does Viyash Scientific Limited pay dividends?
Viyash Scientific Limited pays a Annually dividend of ₹0.5 which represents an annual dividend yield of N/A. See more information on Viyash Scientific Limited dividends here
What is Viyash Scientific Limited’s EPS estimate?
Viyash Scientific Limited’s EPS estimate is 2.
How many shares outstanding does Viyash Scientific Limited have?
Viyash Scientific Limited has 436,875,500 shares outstanding.
What happened to Viyash Scientific Limited’s price movement after its last earnings report?
Viyash Scientific Limited reported an EPS of ₹1.17 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 1.373%.
Which hedge fund is a major shareholder of Viyash Scientific Limited?
Currently, no hedge funds are holding shares in IN:VIYASH
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Viyash Scientific Limited
Viyash Scientific Limited is a global veterinary healthcare company with operations spanning Europe, Asia, and other international markets. It specializes in developing and supplying finished dosage forms for a range of therapeutic applications, including nutritional support, pain relief, parasite control, antibiotic treatments, and gut health solutions. These products cater to various animals like livestock, poultry, and domestic pets. Additionally, the company extends its expertise through analytical testing and specialized veterinary formulation services. Originally established as Sequent Scientific Limited, the company officially adopted the name Viyash Scientific Limited in January 2026. Founded in 1985, its corporate headquarters are situated in Hyderabad, India. Currently, Viyash Scientific Limited functions as a subsidiary of CA Harbor Investments.
Technical Analysis
Akums Drugs and Pharmaceuticals Limited
―
Alembic Pharmaceuticals Limited
―
Caplin Point Laboratories Limited
―
Glenmark Life Sciences Limited
―
Strides Pharma Science Ltd
―